GCIA
APGE icon

Gabelli & Co Investment Advisers’s Apogee Therapeutics APGE Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
+81,645
New +$7.36M 1.58% 16

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Gabelli & Co Investment Advisers's APGE Position: Q2 2026 in Review

Gabelli & Co Investment Advisers opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 81,645 shares worth $10.8M. The stake represents 1.58% of the portfolio and ranks #16 among its holdings.

288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Gabelli & Co Investment Advisers held 81,645 shares of Apogee Therapeutics worth $10.8M as of Q2 2026.
  • Apogee Therapeutics was a new Gabelli & Co Investment Advisers position in Q2 2026.
  • Apogee Therapeutics made up 1.58% of Gabelli & Co Investment Advisers's portfolio in Q2 2026, its #16 holding.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.